Inactivation of pulmonary surfactant and the treatment of acute lung injuries.
Inactivation of pulmonary surfactant may be important in acute lung injury and acute respiratory distress syndrome. Treatment of surfactant dysfunction by instilling exogenous surfactants may improve gas exchange and pulmonary mechanics. Surfactants used for treatment vary in their attributes and effects, so when various surfactants are considered for therapy, resistance to inactivation is an important consideration. Animal models of acute lung injury exist in which the relative merits of surfactants can be compared. We hypothesize that the surfactants most resistant to inactivation in vitro will be the ones that are most effective in treatment of animal models of acute lung injury. Surfactants with higher concentrations of surfactant proteins specificallly A, B, and C) are more resistant to inactivation. Nonionic polymers mimic surfactant proteins in preventing surfactant inactivation under some conditions. Adding nonionic polymers to surfactant containing minimal amounts of SP-B and SP-C markedly improves lung function of animals with lung injury. Making surfactants more "inactivation-proof" may improve surfactant therapy of acute lung injuries.
Taeusch
H W
HW
University of California-San Francisco, USA. btaeusch@sfghpeds.ucsf.edu
Keough
K M
KM
D000328:Adult; D000818:Animals; D004195:Disease Models, Animal; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000187:drug effects; D055370:Lung Injury; D008471:Meconium Aspiration Syndrome / Q000188:drug therapy; D011663:Pulmonary Surfactants / Q000037:antagonists & inhibitors*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy; D013501:Surface-Active Agents / Q000627:therapeutic use
D011663:Pulmonary Surfactants; D013501:Surface-Active Agents